Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Heart

• Publication date

  2012-07-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/heartjnl-2012-302371PMID 22851683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial

  2012cited by this paper
• Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention

  2012cited by this paper
• Major adverse cardiac events among postpercutaneous coronary intervention patients on clopidogrel and proton pump inhibitors.

  2012cited by this paper
• Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.

  2012cited by this paper
• Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.

  2012cited by this paper
• Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting:

  2012cited by this paper
• One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study

  2012cited by this paper
• Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial

  2012cited by this paper
• A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.

  2012cited by this paper
• Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.

  2012cited by this paper
• Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)

  2011cited by this paper
• Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors

  2011cited by this paper
• Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.

  2011cited by this paper
• Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects: Results of a Prospective, Randomized, Crossover Study

  2011cited by this paper
• Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention: An Analysis From the Guthrie Health Off-Label Stent (GHOST) Investigators

  2011cited by this paper
• Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial.

  2011cited by this paper
• Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes.

  2011cited by this paper
• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  2011cited by this paper
• Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation

  2011cited by this paper
• Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome

  2011cited by this paper
• Randomized double‐blind placebo‐controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel

  2011cited by this paper
• Response to Clopidogrel With Proton Pump Inhibitors: Safe or Not?

  2011cited by this paper
• Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo‐Controlled, Crossover Comparison Studies

  2011cited by this paper
• Combined influence of proton‐pump inhibitors, calcium‐channel blockers and CYP2C19*2 on on‐treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention

  2011cited by this paper
• Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry

  2011cited by this paper
• Esomeprazole but Not Pantoprazole is Associated with Lower Plasma Concentrations of Clopidogrel's Active Metabolite

  2011cited by this paper
• Pantoprazole Does Not Influence the Antiplatelet Effect of Clopidogrel-A Whole Blood Aggregometry Study After Coronary Stenting

  2010cited by this paper
• Effect of an increased clopidogrel maintenance dose or lansoprazole co‐administration on the antiplatelet response to clopidogrel in CYP2C19‐genotyped healthy subjects

  2010cited by this paper
• Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study

  2010cited by this paper
• Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor After Stent Placement for Acute Myocardial Infarction

  2010cited by this paper
• Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use

  2010cited by this paper
• Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes.

  2010cited by this paper
• Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention

  2010cited by this paper
• Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.

  2010cited by this paper
• The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.

  2010cited by this paper
• Differential Effects of Esomeprazole on the Antiplatelet Activity of Clopidogrel in Healthy Individuals and Patients after Coronary Stent Implantation

  2010cited by this paper
• Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation

  2010cited by this paper
• Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome.

  2010cited by this paper
• Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors

  2010cited by this paper
• The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by 5 Different Platelet Function Tests

  2010cited by this paper
• Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.

  2010cited by this paper
• Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.

  2010cited by this paper
• ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

  2010cited by this paper
• Pharmacodynamic Effects of Concomitant Versus Staggered Clopidogrel and Omeprazole Intake: Results of a Prospective Randomized Crossover Study

  2010cited by this paper
• Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.

  2010cited by this paper
• Effects of omeprazole on the antiplatelet activity of clopidogrel.

  2010cited by this paper
• [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].

  2010cited by this paper
• Clopidogrel and proton pump inhibitors: can near patient testing help in the tailoring of dual antiplatelet prescription?

  2010cited by this paper
• Clopidogrel with or without omeprazole in coronary artery disease.

  2010cited by this paper
• Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.

  2010cited by this paper
• Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.

  2010cited by this paper
• Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors

  2010cited by this paper
• Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.

  2009cited by this paper
• Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

  2009cited by this paper
• Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.

  2009cited by this paper
• A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

  2009cited by this paper
• Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel

  2009cited by this paper
• The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease

  2009cited by this paper
• Concomitant Use of Clopidogrel and Proton Pump Inhibitors or Cimetidine After Acute Myocardial Infarction Would Increase the Risk of Re-Infarction

  2009cited by this paper
• Cytochrome p-450 polymorphisms and response to clopidogrel.

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

  2009cited by this paper
• Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

  2008cited by this paper
• ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

  2008cited by this paper
• Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.

  2008cited by this paper
• Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

  2008cited by this paper
• Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin

  2006cited by this paper
• Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

  2005cited by this paper
• Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

  2004cited by this paper
• Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative.

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• The way I see it: House officers need formal career development

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection

  1999cited by this paper
• Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole

  1999cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper

• Clopidogrel versus aspirin for coronary artery disease.

  2026cites this paper
• Helicobacter pylori, helicobacteriosis and associated diseases (VIII Moscow Agreements on the diagnosis and treatment of helicobacteriosis in adults and children) A Clinical Guide for Physicians

  2024cites this paper
• Antithrombotics and Gastrointestinal Prophylaxis: A Systematic Review

  2023cites this paper
• Effect of esomeprazole on lipid profile in patients with peptic ulcer

  2021cites this paper
• Underutilization of Peptic Ulcer Disease Prophylaxis Among Elderly Users of Antiplatelets and Anticoagulants

  2020cites this paper
• Drug interactions with CYP enzymes

  2020cites this paper
• Clopidogrel efficacy with concomitant drug therapy in patients undergoing percutaneous coronary intervention

  2020cites this paper
• Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel.

  2019cites this paper
• Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents

  2019influential citation
• Extension Activities of a Uruguayan University in the Context of Pharmaceutical Care Education in the Community

  2019cites this paper
• Heartburn

  2019cites this paper
• Prevention of cardiovascular outcomes in diabetic patients with atrial fibrillation: direct oral anticoagulants or warfarin?

  2019cites this paper
• Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry.

  2019cites this paper
• Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy

  2019cites this paper
• Protonpompremmers bij gebruik van clopidogrel

  2019cites this paper
• Role of aspirin in primary prevention of cardiovascular disease

  2019cites this paper
• A Prospective Observational Study on Evidence-Based and Unlicensed Indications for Proton Pump Inhibitors in Inpatients of a Tertiary Care Hospital

  2018cites this paper
• Reply.

  2018cites this paper
• Pantoprazole reduces vascular relaxation in-vitro and ex-vivo and interferes with blood coagulation in an animal model.

  2018cites this paper
• Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000–2016

  2018cites this paper
• Drug–Drug Interactions as a Complication of Maxillofacial Surgery

  2018cites this paper
• Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.

  2017cites this paper
• Decrease in Switches to ‘Unsafe’ Proton Pump Inhibitors After Communications About Interactions with Clopidogrel

  2017cites this paper
• Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review.

  2017cites this paper
• Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients

  2017cites this paper
• Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes.

  2017cites this paper
• Comparison of prophylactic effect of UGIB and effects on platelet function between PPIs and H2RAs combined with DAPT: systematic review and meta-analysis

  2017cites this paper
• Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs.

  2017cites this paper
• Protonenpumpenhemmer – Nebenwirkungen und Komplikationen der langfristigen Protonenpumpenhemmereinnahme

  2017cites this paper
• Proton-pump inhibitors: understanding the complications and risks

  2017cites this paper
• Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis

  2016cites this paper
• Potentially Serious Drug-Drug Interactions in Older Patients Hospitalized for Acute Ischemic and Hemorrhagic Stroke

  2016cites this paper
• Connections between nutritional status and proton pump inhibitor therapy in patients scheduled for cardiovascular rehabilitation after treatment for ischaemic and valvular heart disease.

  2016influential citation
• Does hospital admission provide an opportunity for improving pharmacotherapy among elderly inpatients

  2016cites this paper
• Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel – proton pump inhibitor interaction

  2016cites this paper
• Adverse Effects Associated With Proton Pump Inhibitors.

  2016cites this paper
• Potential drug-drug interactions in a Brazilian teaching hospital: age-related differences?

  2016cites this paper
• Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After PCI

  2016cites this paper
• Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Española de Patología Digestiva.

  2016cites this paper
• The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway

  2016cites this paper
• Acute Coronary Syndromes, Gastrointestinal Protection, and Recommendations Regarding Concomitant Administration of Proton-Pump Inhibitors (Omeprazol/Esomeprazole) and Clopidogrel.

  2016cites this paper
• Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy.

  2016cites this paper
• Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis

  2015cites this paper
• Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?

  2015cites this paper
• Should proton pump inhibitors be withheld from patients taking clopidogrel? The issue that has been giving me heartburn!

  2015cites this paper
• Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study

  2015cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

  2015cites this paper
• Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manag

  2015cites this paper
• Revisiting the Clopidogrel-Proton Pump Inhibitor Interaction: From Bench to Bedside.

  2015cites this paper
• Effect of Esomeprazole With/Without Acetylsalicylic Acid, Omeprazole and Lansoprazole on Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers

  2014cites this paper
• PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies.

  2014cites this paper
• Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study.

  2014cites this paper
• Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding

  2014cites this paper
• ALMANAC: THE NATIONAL SOCIETY JOURNALS PRESENT SELECTED RESEARCH THAT HAS DRIVEN RECENT ADVANCES IN CLINICAL CARDIOLOGY. STABLE CORONARY ARTERY DISEASE

  2014cites this paper
• Newer Antiplatelet Agents for Interventional Indications

  2014cites this paper
• ESC National Societies Cardiovascular Journals EditorsNetwork

  2014cites this paper
• Esc

  2014cites this paper
• 36. Proton Pump Inhibitors and Clopidogrel

  2014cites this paper
• Almanac 2013: Acute coronary syndromes.

  2014cites this paper
• Enfermedad coronaria estable

  2014cites this paper
• The dangers of proton pump inhibitor therapy.

  2014cites this paper
• Almanac 2013.:stabilna koronarna bolest srca.

  2014cites this paper
• Альманах-2013: стабільна ішемічна хвороба серця*

  2014cites this paper
• Clustering of Acute and Subacute Stent Thrombosis Related to the Introduction of Generic Clopidogrel

  2014cites this paper
• Optimising pharmacotherapy for secondary prevention of non‐invasively managed acute coronary syndrome

  2014cites this paper
• Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review.

  2014cites this paper
• Langzeitbehandlung mit Protonenpumpenhemmern

  2013cites this paper
• Aspirin and Clopidogrel for Prevention of Ischemic Stroke

  2013cites this paper
• Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care.

  2013cites this paper
• Proton Pump Inhibitors and Potential Interactions with Clopidogrel: An Update

  2013cites this paper
• Atherosclerotic Coronary Artery Disease

  2013cites this paper
• Bibliography çEditors ’ selectionof current world literature

  2013cites this paper
• Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry

  2013cites this paper
• Pharmacological interactions: the next frontier?

  2013cites this paper
• The impact of the environment on diseases and drugs.

  2013cites this paper
• Almanac 2013: acute coronary syndromes.

  2013cites this paper
• Benefits and pitfalls of cardiovascular medication in seniors

  2013cites this paper
• CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Antiplatelet Action of Clopidogrel

  2013cites this paper
• Almanac 2013: stable coronary artery disease

  2013cites this paper
• Almanah 2013.: akutni koronarni sindromi Almanac 2013: acute coronary syndromes

  2013cites this paper
• Almanac 2013: cardiac arrhythmias and pacing-an editorial overview of selected research that has driven recent advances in clinical cardiology.

  2013cites this paper
• Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance

  2013cites this paper
• Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events

  2013cites this paper
• The influence of P2Y12 antagonists on vascular NO signalling

  2013cites this paper
• Almanac 2013: stable coronary artery disease

  2013cites this paper
• ESC National Societies Cardiovascular Journals EditorsNetwork

  2013cites this paper
• Platelet antiaggregants in stroke prevention.

  2013cites this paper
• Almanac 2013: acute coronary syndromes

  2013cites this paper
• Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).

  2013cites this paper
• Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia

  2012cites this paper
• Stable coronary artery disease

  2011cites this paper
• Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology.

  2011cites this paper